United Therapeutics Corporation (UTHR)
UTHR: Notification
Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb - Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
Exicure Inc. (XCUR)
Exicure, Inc. - Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting
Bristol-Myers Squibb Co. (BMYMP)
Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
Roche Holding Ltd (RHHBY)
Genentech Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas
Incyte Corporation (INCY)
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
Exicure Inc. (XCUR)
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting
Genmab (GMAB)
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
Johnson & Johnson (JNJ)
Johnson & Johnson - Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference